Dr. Choueiri on the Future Examination of Adjuvant Pembrolizumab in RCC

Video

In Partnership With:

Toni Choueiri, MD, discusses the future examination of adjuvant pembrolizumab in renal cell carcinoma.

Toni Choueiri, MD, medical director, International Strategic Initiatives, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, Jerome and Nancy Kohlberg Chair and Professor of Medicine, Harvard Medical School, discusses the future examination of adjuvant pembrolizumab (Keytruda) in renal cell carcinoma (RCC).

In November 2021, the FDA approved pembrolizumab as adjuvant therapy in patients with high-risk RCC, Choueiri says. Currently, clinicians are aiming to understand the data in more detail, leading to the LITESPARK-022 trial (NCT05239728), Choueiri adds. In this trial, the control arm is not placebo, but rather adjuvant pembrolizumab, and the trial is open for accrual internationally, Choueiri explains.

LITESPARK-022 will utilize pembrolizumab as the control arm, whereas the experimental arm will be pembrolizumab plus belzutifan (MK-6482), which has shown activity in metastatic disease, Choueiri concludes.

Related Videos
John Shen, MD
Tatyana Feldman, MD
A panel of 4 experts on bladder cancer
Matthew Milowsky, MD, FASCO, an expert on bladder cancer
Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center
Riccardo Lencioni, MD, FSIR, EBIR
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD